What is Butotal?
Albuterol is used to treat or prevent bronchospasm in patients with asthma, bronchitis, emphysema, and other lung diseases. This medicine is also used to prevent wheezing caused by exercise (exercise-induced bronchospasm).
Albuterol belongs to the family of medicines known as adrenergic bronchodilators. Adrenergic bronchodilators are medicines that are breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. They relieve cough, wheezing, shortness of breath, and troubled breathing by increasing the flow of air through the bronchial tubes.
This medicine is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, albuterol is used in certain patients with the following medical condition:
- Hyperkalemia (too much potassium in the blood).
Butotal indications
As a bronchodilator in the treatment of bronchospasm associated with bronchial asthma, emphysema and chronic bronchitis and other conditions associated with reversible airways obstruction. Butotal also decreases uterine contractility and arrests premature labor.
Uses of Butotal in details
Butotal is used to prevent reversible airways obstruction occurring during asthma, infections of airway passages (bronchitis), lung disorder in which the flow of air to the lungs is blocked (emphysema), and other lung diseases.
Butotal description
Each 200 mcg/dose powder for inhalation solution contains Salbutamol sulphate equivalent to Butotal 200 mcg per metered dose. The dose, which the patient gets through the mouthpiece of the device is Butotal 180 mcg.
It contains lactose monohydrate (milk protein) as excipient.
The Butotal multiple dose powder inhaler contains 200 doses of finely powdered Butotal sulphate mixed in a small quantity of lactose. The amount of drug received by the patient (180 mcg/dose) corresponds to that from Butotal inhalation aerosol. The dose to be inhaled is released from the container by pressing the device between the thumb and forefinger. This is followed by inhalation through the device. As a result, Butotal particles are transferred to their target, the lungs. Use of the Butotal does not require coordination of actuation of the dose and inhalation.
Butotal dosage
Tablet: Adults: Usual Dose: 4 mg or 10 mL (2 tsp) of syrup. If adequate bronchodilation is not obtained, each single dose may be gradually increased to as much as 8 mg or 20 mL (4 tsp) of syrup.
To be taken every 6 or 8 hrs.
In some patients known to be unusually sensitive to β-adrenergic stimulant drugs who obtain adequate relief with 5 mL of syrup, it is advisable to initiate treatment with 5 mL (1 tsp) of syrup 3 or 4 times a day.
Children >12 years: 2-4 mg or 5-10 mL (1-2 tsp) of syrup; 6-12 years: 2 mg or 5 mL (1 tsp) of syrup; 2-6 years: 1-2 mg or 2.5-5 mL (½-1 tsp) of syrup.
Nebulizing Solution: Adults and Adolescents: Usual Dose: The usual initial dose of Butotal by wet inhalation is 2.5-5 mg. Treatment may be repeated up to 4 times daily. In adults, higher dosing up to 40 mg/day can be given under strict medical supervision in hospital for the treatment of severe airway obstruction.
Children up to 12 years: Dosage has not been established. Note: As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice.
Administration: Butotal 1 mg/mL nebulizing solution for inhalation is given undiluted using a nebulizer, under the direction of a physician. However, if prolonged administration is desired (>10 min), the solution can be diluted with 0.9% sodium chloride solution.
Direction for Dilution/Prolonged Inhalation: Pipette 2.5-5 mL (equivalent to 2.5-5 mg Butotal, as sulfate) of Butotal nebulizing solution from the bottle by using a calibrated medicine dropper provided in the pack. Drop the solution into an electric nebulizer and dilute it with 2-4 mL normal saline solution and start inhalation. Any unused solution in the chamber of the nebulizer must be discarded. Repeat the same procedure every 8 hrs in a 24-hr period.
Butotal interactions
If additional adrenergic drugs are administered to patients using Butotal Easyhaler they should be used with caution to avoid deleterious cardiovascular effects. Patients treated with monoamine oxidase inhibitors or tricyclic antidepressants should be followed clinically in the beginning of Butotal treatment, because the action of Butotal on the vascular system may be potentiated. Beta-blockers eg, propranolol, inhibit the effect of Butotal like that of any other β2-agonists.
The simultaneous administration of xanthines, corticosteroids or potassium excreting diuretics may increase hypokalemia.
Incompatibilities: Not applicable.
Butotal side effects
See also:
What are the possible side effects of Butotal?
Butotal sulfate is generally well tolerated and serious toxic effects are few. The adverse reactions to Butotal sulfate are similar in nature to reactions to other sympathomimetic agents, although the incidence of certain cardiovascular effects is lower with Butotal sulfate. The most frequent adverse reactions to Butotal sulfate are nervousness and tremor. Other reported reactions are headache, tachycardia and palpitations, muscle cramps, insomnia, nausea, weakness and dizziness. Rare cases of urticaria, angioedema, rash and oropharyngeal edema have been reported after the use of Butotal sulfate. The reactions are generally transient in nature and it is usually not necessary to discontinue treatment with Butotal sulfate. Inform the physician of the unwanted effects after administering.
Butotal contraindications
Hyperthyroidism and cardiac disease. Butotal may interact with monoamine oxidase inhibitors and should not be given to patients receiving such treatment or within 14 days after stopping treatment.
Use in pregnancy & lactation: Safety in pregnancy and lactating women has not been established.
Butotal is not indicated for the prevention of premature labor associated with toxemia of pregnancy or ante partum hemorrhage, nor should it be used for threatened abortion during the 1st and 2nd trimesters of pregnancy.
Active ingredient matches for Butotal:
Salbutamol in Chile, Peru.
Beclometasone in Chile.
| Unit description / dosage (Manufacturer) | Price, USD |
| Solution; Inhalation, Oral; Albuterol 5 mg / ml | |
List of Butotal substitutes (brand and generic names): | |
| Butoas (Venezuela) | |
| Butovent (Brazil, Egypt, Jordan, Kuwait, Lebanon, Luxembourg, Oman, Saudi Arabia, Sri Lanka, Syria) | |
| Butovent 100 mcg/1 dose x 1 average xГІt 200 laГ n (Chiesi) | |
| Butovent 100 | |
| Butovent Pulvinal (Brazil) | |
| Butuhale (Peru) | |
| Buventol (Finland, Lithuania, Malaysia, Norway, Sweden, Taiwan) | |
| Powder; Inhalation; Albuterol Sulfate 100 mcg / dose (Actavis) | |
| Buventol 100 mcg/1 dose x 200 doses (Actavis) | |
| Buventol 200 mcg/1 dose x 200 doses (Actavis) | |
| Buventol 200 µg/adag (Hungary) | |
| Buventol Easyhaler (Austria, Czech Republic, Denmark, Estonia, Hungary, Latvia, Malaysia, Norway, Poland, Singapore, Sweden, Thailand) | |
| Powder; Inhalation; Albuterol Sulfate 100 mcg / dose (Orion Pharma) | |
| Buventol Easyhaler 100 mcg/1 dose x 200 doses, with protective cover (Orion Pharma) | |
| Buventol Easyhaler 200 mcg/1 dose x 200 doses, with protective cover (Orion Pharma) | |
| Buventol Easyhaler 200 mcg/1 dose x 200 doses (Orion Pharma) | |
| Buventol Easyhaler 100 mcg/1 dose x 200 dose x 1's (Orion Pharma) | |
| Powder; Inhalation; Albuterol Sulfate 200 mcg / dose (Orion Pharma) | |
| Buventol Easyhaler inhalation powd cap 100 mcg/dose 200 dose x 1's (Orion Pharma) | |
| Buventol Easyhaler inhalation powd cap 200 mcg/dose 200 dose x 1's (Orion Pharma) | |
| Candasia-B (India) | |
| Candasia-B Clotrimazole 1 % w/w, Beclometasone 0.025 % w/w. CRM / 15g (Willow) | $ 0.42 |
| 15g (Willow) | $ 0.42 |
| CANDASIA-B cream 15g (Willow) | $ 0.42 |
| Candeol-B (India) | |
| Candeol-B Clotrimazole 1 % w/w, beclometasone 0.025 % w/w. OINT / 15g (Olcare (Olski)) | $ 0.47 |
| Candeol-B Clotrimazole 1 % w/w, beclometasone 0.025 % w/w. LOTION / 15ml (Olcare (Olski)) | $ 0.47 |
| CANDEOL-B oint 15g (Olcare (Olski)) | $ 0.47 |
| CANDEOL-B lotion 15ml (Olcare (Olski)) | $ 0.47 |
| Candex-B (India) | |
| Candex-B Clotrimazole 1 %, beclometasone 0.025 %. OINT / 15g (Olcare (Excare)) | $ 0.47 |
| CANDEX-B oint 15g (Olcare (Excare)) | $ 0.47 |
| Candex-NB (India) | |
| Candex-NB Clotrimazole 1 % w/w, beclometasone 0.025 % w/w, neomycin 0.1 % w/w. CRM / 15g (Olcare (Excare)) | $ 0.47 |
| CANDEX-NB cream 15g (Olcare (Excare)) | $ 0.47 |
| Candimin (India) | |
| Candimin Chloramphenicol 5 % w/v, clotrimazole 1 % w/v, beclometasone dipropionate0.025 % w/v, lidocainehydrochloride 2 % w/v. EAR DPS / 5ml (Minova) | $ 0.40 |
| CANDIMIN ear drops 5ml (Minova) | $ 0.40 |
| Canditas-Bgn (India) | |
| Canditas-Bgn Clotrimazole 1 %, beclometasone dipropionate0.025 % w/w, neomycin 0.5 %. CRM / 10g (Intas) | $ 0.33 |
| Canditas-Bgn Clotrimazole 1 %, beclometasone dipropionate0.025 % w/w, neomycin 0.5 %. CRM / 15g (Intas) | $ 0.40 |
| Canditas-Bgn Clotrimazole 1 %, beclometasone dipropionate0.025 % w/w, neomycin 0.5 %. CRM / 5g (Intas) | $ 0.23 |
| CANDITAS-BGN cream 10g (Intas) | $ 0.33 |
| CANDITAS-BGN cream 15g (Intas) | $ 0.40 |
| CANDITAS-BGN cream 5g (Intas) | $ 0.23 |
| Candivate Cream (India) | |
| Candivate Cream Clotrimazole 1 % w/w, Beclometasone dipropionate0.025 % w/w, Neomycin sulphate0.5 % w/w. CRM / 15g | $ 0.47 |
| Candivate Cream Clotrimazole 1 % w/w, Beclometasone dipropionate0.025 % w/w, Neomycin sulphate0.5 % w/w. CRM / 5g | $ 0.17 |
| Candivate Cream Clotrimazole 1% w/w, beclometasone Dipropionate0.025% w/w, Neomycin Sulphate0.5% w/w CRM / 15g | $ 0.47 |
| Candivate Cream Clotrimazole 1% w/w, beclometasone Dipropionate0.025% w/w, Neomycin Sulphate0.5% w/w CRM / 5g | $ 0.17 |
| 15g | $ 0.47 |
| 5g | $ 0.17 |
See 2422 substitutes for Butotal | |
References
- DailyMed. "ALBUTEROL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Salbutamol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Salbutamol". http://www.drugbank.ca/drugs/DB01001 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Butotal are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Butotal. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
